Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) rose 4.6% on Friday . The company traded as high as C$0.92 and last traded at C$0.91. Approximately 4,855 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 51,231 shares. The stock had previously closed at C$0.87.
Medicenna Therapeutics Price Performance
The business has a 50 day moving average price of C$1.02 and a two-hundred day moving average price of C$1.25. The stock has a market cap of C$68.08 million, a PE ratio of -2.51 and a beta of 1.21. The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40.
About Medicenna Therapeutics
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Featured Articles
- Five stocks we like better than Medicenna Therapeutics
- Energy and Oil Stocks Explained
- X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back
- How to Profit From Growth Investing
- 3 Oversold Stocks Flashing Bullish Reversal Signals
- Golden Cross Stocks: Pattern, Examples and Charts
- With Novo Nordisk’s CEO Out, Wall Street Wants an American Leader
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
